Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | CASP1 | P29466 | 1/20 | 0.66 |
| ▸ | CASP7 | P55210 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787403 | 0.91 | MAPT (0.58) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL3784669 | 0.85 | MAPT (0.51) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL3794233 | 0.85 | MAPT (0.68) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL360551 | 0.84 | HTR2C (0.52) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL29684402 | 0.84 | HTR2C (0.52) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL3781671 | 0.82 | MAPT (0.54) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL359320 | 0.82 | HTT (0.51) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL14194196 | 0.81 | MAPT (0.49) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL12505493 | 0.81 | MAPT (0.49) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL394963 | 0.81 | MAPT (0.96) | MAPTKDM4EKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035771-B2 | Mercaptonicotinic acid compound and preparation method and use thereof | INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES, PR CHINA (CN) | 2018-07-31 | — | — | US | disclosed |
| US-20160083347-A1 | MERCAPTONICOTINIC ACID COMPOUND AND PREPARATION METHOD AND USE THEREOF | INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES, PR CHINA (CN) | 2016-03-24 | — | — | US | disclosed |
| CN-103265478-B | Mercaptonicotinic acid compounds and preparation method thereof | THE SECOND MILITARY MEDICAL UNIVERSITY (CN) | 2015-09-30 | — | — | CN | disclosed |
| CN-103265478-A | Mercaptonicotinic acid compounds and preparation method thereof | UNIV PLA 2ND MILITARY MEDICAL | 2013-08-28 | — | — | CN | disclosed |
| EP-2593457-A1 | PYRAZOLO [1, 5A]PYRIMIDINE AND THIENO [3, 2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007375-A1 | PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| EP-0362729-A1 | Process for producing water insoluble azo dyes on the fibre | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083347-A1 | MERCAPTONICOTINIC ACID COMPOUND AND PREPARATION METHOD AND USE THEREOF | PREP, ENGASE, ADAMTS13 | MAPT 1407/4885KDM4E 2138/4885KMT2A 3401/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | MAPT 3312/4885KDM4E 2606/4885KMT2A 1474/4885 |
| US-10035771-B2 | Mercaptonicotinic acid compound and preparation method and use thereof | PREP, ENGASE, ADAMTS13 | MAPT 1407/4885KDM4E 2138/4885KMT2A 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.